Bone Biologics Corporation BBLG · Stock Open Bone Biologics Corporation in new tab
Bone Biologics Corporation Analysis (BBLG)
Is Bone Biologics Corporation a good investment? Bone Biologics Corporation (BBLG) is currently trading at 0.4875 USD.
Earnings Schedule: Bone Biologics Corporation is expected to release its next earnings report on Nov. 13, 2026. The market consensus estimate for Forward EPS is -0.67.
Investor FAQ
Does Bone Biologics Corporation pay a dividend?
No, it does not currently pay a dividend.
What asset class is Bone Biologics Corporation?
Bone Biologics Corporation is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 13, 2026. The company currently has a trailing EPS of -1.37.
Company Profile
Bone Biologics Corporation, a medical device company, focuses on bone regeneration in spinal fusion using the recombinant human protein in the United States. Its lead product is NELL-1/DBM medical device, an osteopromotive recombinant protein, which provides target specific control over bone regeneration. The company also develops NB1, a NELL-1/DBM fusion device for use in lumbar spinal fusion, as well as spine implants, non-union trauma cases, and osteoporosis applications. It serves spine surgeons and patients with a skeletal bone defect or bone-related condition in their spine. The company has a license agreement with the UCLA Technology Development Group to develop and commercialize NELL-1 for spinal fusion by local administration, osteoporosis, and trauma applications. Bone Biologics Corporation was founded in 2004 and is headquartered in Burlington, Massachusetts.
| Split Date | Split Ratio to 1 |
|---|---|
| June 7, 2023 | 1:30 |
| Dec. 20, 2023 | Needs review |
| June 10, 2025 | 1:6 |
Community Discussion